Clinical Validation Archives

Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial
Gallery
Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial

Acta Medica Academica, Audeh, Clinical Validation, Evidence, MammaPrint

Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial

PUBLICATION: Acta Medica Academica. Volume 48 (2) August 2019 AUTHOR: Read More

kevin2020-06-15T17:51:27-07:00August 2nd, 2019|Acta Medica Academica, Audeh, Clinical Validation, Evidence, MammaPrint|

The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer
Gallery
The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer

Annals of Surgical Oncology, Clinical Validation, Evidence, MammaPrint, Steenhoven

The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer

PUBLICATION: Ann Surg Oncol (2019) 26: 3495. https://doi.org/10.1245/s10434-019-07511-8. AUTHORS: J.E.C. Read More

kevin2020-06-15T17:53:52-07:00June 17th, 2019|Annals of Surgical Oncology, Clinical Validation, Evidence, MammaPrint, Steenhoven|

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
Gallery
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

BluePrint, Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, Wuerstlein

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More

kevin2020-06-15T17:56:37-07:00June 1st, 2019|BluePrint, Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, Wuerstlein|

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Gallery
Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

Clinical Validation, Evidence, JAMA Oncololgy, MammaPrint, Tsai

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Read More

kevin2020-06-15T17:59:50-07:00January 11th, 2018|Clinical Validation, Evidence, JAMA Oncololgy, MammaPrint, Tsai|

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
Gallery
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Clinical Validation, Esserman, Evidence, JAMA Oncol., JAMA Oncology, MammaPrint

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS: Laura J. Esserman, MD, Read More

kevin2020-06-15T18:01:56-07:00November 2nd, 2017|Clinical Validation, Esserman, Evidence, JAMA Oncol., JAMA Oncology, MammaPrint|

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk
Gallery
Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, van't Veer

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Read More

kevin2020-06-15T18:02:13-07:00November 1st, 2017|Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, van't Veer|

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study
Gallery
Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study

Clinical Validation, Evidence, Journal of Clinical Oncology, Kuijer, MammaPrint

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study

PUBLICATION: Journal of Clinical Oncology 35, no. 24 (August 20, Read More

kevin2020-06-15T18:03:07-07:00August 20th, 2017|Clinical Validation, Evidence, Journal of Clinical Oncology, Kuijer, MammaPrint|

Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.
Gallery
Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.

Aalders, Clinical Validation, European Journal of Cancer, Evidence, MammaPrint

Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.

PUBLICATION: European Journal of Cancer. July 2017, Volume 79, Pages Read More

kevin2020-06-15T18:40:28-07:00July 2nd, 2017|Aalders, Clinical Validation, European Journal of Cancer, Evidence, MammaPrint|

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer
Gallery
Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer

Beumer, Biomarker Insights, Clinical Validation, Evidence, MammaPrint

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer

PUBLICATION: Biomark Insights. 2016; 11: 139–146. doi: 10.4137/BMI.S38435 AUTHORS: Inès Read More

kevin2020-06-15T18:43:57-07:00December 11th, 2016|Beumer, Biomarker Insights, Clinical Validation, Evidence, MammaPrint|

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.
Gallery
Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, Nunes

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. https://doi.org/10.1007/s10549-016-3949-y09. AUTHORS: Read More

kevin2020-06-15T18:44:31-07:00August 27th, 2016|Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, Nunes|

Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial

The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study

Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

Kenyon Sweeney

Christy Garcia

PROF. LAURA VAN ‘T VEER, PhD

ROOPOM BANERJEE